01 September 1997
Effect of ornithine-aspartate infusion on elevated serum ammonia concentration in cirrhotic patients - results of a randomized, placebo-controlled double-blind multicentre trial
Janos Feher, Istvan Lang, Arpad Gogl, Laszlo Varga, Laszlo Varga, Gabor Tompos, Laszlo PronaiMed Sci Monit 1997; 3(5): CR669-673 :: ID: 501567
Abstract
Eighty patients were included in a randomized, double-blind, placebo-controlled multicentre trial to determine the effect of L-ornithine-L-aspartate (Hepa-Merz¨) infusion on serum ammonia level in patients with liver cirrhosis accompanied by hyperammonaemia.Fourty patients received ornithine-aspartate (20 g in 250 ml 0,9% NaCl infusion solution administered intravenously during four hours) and 40 patients received placebo (250 ml 5% fructose solution). The follow-up time was seven days. Patients had alcoholic liver cirrhosis with hyperammonaemia (venous ammonia > 50 µmol/l). Patients treated with other hepatotherapeutic agents and those having alcohol withdrawal syndrome, consumption of alcohol during the study, gastrointestinal bleeding, pregnancy, severe concomitant diseases or fructose intolerance were excluded from the trial. Effect of treatment was evaluated by the clinical course and laboratory parameters of patients (venous ammonia level, g-GT, AST, ALT, AP, glucose, bilirubin, ChE, BUN, creatinine, albumin, prothrombin and hematological parameters) measured at 1, 3, 5 and 7 days of treatment.The seven-day ornithine-aspartate infusion therapy resulted in a significant decrease (p<0,05) of fasting ammonia concentration (-32%) when compared with that in the placebo group (-15%). There was no significant improvement in the routine laboratory parameters measured. Good tolerability and low rate of side effects were reported by the patients. In view of its demonstrated effect, ornithine-aspartate infusion can be considered as an effective therapy to decrease elevated serum ammonia level in cirrhotic patients.
Keywords: Liver Cirrhosis, ornithine-aspartate, hyperammonaemia
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...Med Sci Monit In Press; DOI: 10.12659/MSM.943797
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952